Australia's Prescient Therapeutics soars on orphan drug designation for cancer therapy

Prescient Therapeutics

15/07/2022 03:09

** Shares of Prescient Therapeutics  PTX.AX  jump as much as
25% to A$0.20, their highest level since June 8
    ** Says the U.S. Food and Drug Administration (FDA) granted
orphan drug designation to PTX-100, which treats peripheral
T-cell lymphoma, a type of blood cancer  urn:newsml:reuters.com:*:nASX5BQMWL 
    ** Orphan drug designation gives PTX guaranteed market
exclusivity of seven years from the grant of regulatory approval
    ** Stock logs best intraday gain since June 24 
    ** PTX down 30.4% YTD as of last close 

 (Reporting by Harshita Swaminathan)
 ((Harshita.Swaminathan@thomsonreuters.com))